Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Galapagos
Deal Size : $234.7 million
Deal Type : Acquisition
Galapagos to Acquire CellPoint And AboundBio to Accelerate Access to Next-Generation Cell Therapies
Details : CellPoint has developed, in a strategic collaboration with Lonza, a novel point-of-care supply model, which offers the potential for efficient, 7-day delivery of CAR-T therapies and avoids complex logistics, thereby addressing important limitations of cu...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $130.4 million
June 21, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Galapagos
Deal Size : $234.7 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 23, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer
Details : 99m-Tc Ethylenedicysteine-Deoxyglucose is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
July 14, 2011
Reset All
